Element Biosciences Accelerates Rollout of Direct in Sample Sequencing for the AVITI24™ Intelligent Multiomics System to Meet Growing Demand
SAN DIEGO--(BUSINESS WIRE)-- Element Biosciences, Inc., a company democratizing access to advanced life science solutions, today announced the accelerated rollout and availability of direct in sample sequencing on AVITI24, the first intelligent multiomics system. Direct in sample sequencing, or DISS, is a high-demand and transformative technology that unlocks unprecedented research possibilities across a variety of new use cases, including lineage tracing and CRISPR screens with simultaneous optical phenotyping, targeted RNA sequencing, custom protein analysis, and more – all completely library-prep free. Direct in sample sequencing technology will be available for preorder May 21, 2025.
"Direct in sample sequencing is a leap forward that removes any and all library prep entirely, enabling scientists to profile RNA, proteins, phosphoproteins, and cell morphology from a single sample in one automated run. It opens the door to smart, scalable biology—shifting the field to high-resolution, high-value insights at unprecedented speed," said Michael Previte, Co-founder and Chief Technology Officer of Element Biosciences.
New research from the AVITI24 platform, including abstracts and workshop sessions, will be presented at the American Association for Cancer Research (AACR) annual meeting in Chicago from April 25-30. Attendees can meet the Element team at Booth #4035 and Meeting Room MR-119.
AACR abstract presentations exploring new upgrades to the AVITI24 platform are listed below and can also be found on our website.
An automated workflow for optical pooled screens with massively multiplexed phenotypic readouts on AVITI24
Sunday, April 27, 2:00 PM - 5:00 PM
Avtar Singh, PhD, Genentech
LB042 | Section 52
A cancer patient survival study facilitated by an integrated enrichment workflow streamlined DNA and RNA sequencing of biopsy samples
Sunday, April 27, 2:00 PM - 5:00 PM
June Zhao, PhD
1020 /22 - Section 42
Unraveling the mechanism of action for research of cancer therapies using AVITI24
Monday, April 28, 2:00 PM - 5:00 PM
Vivian Dien, PhD
3702 /1-Section 47
A novel integrated target capture and rapid sequencing workflow for myeloid malignancy mutation detection within 12 hours
Tuesday, April 29, 9:00 AM - 12:00 PM
Kyle S. Metcalfe
4080 /17 - Section 10
To learn more about DISS and AVITI24, book a meeting with Element at AACR via Calendly.
About Element Biosciences, Inc.
Element Biosciences is a life science company democratizing access to advanced biological tools, driving impactful discoveries to benefit humanity. Through innovating every fundamental element of a biological assay system, Element empowers customers with affordable, high-quality data and an improved user experience, which in turn will accelerate scientific discoveries. To learn more about Element, please visit www.elementbiosciences.com and follow us on LinkedIn, X (Twitter), and Facebook.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
4 hours ago
- Yahoo
CRISPR Therapeutics (NasdaqGM:CRSP) Sees 16% Stock Price Surge Over Last Month
CRISPR Therapeutics experienced a 15.8% increase in its share price over the past month. While specific recent news on the company was not available to credit for this movement, it's worth noting that during this period, the broader market rose by 1.8%, and has seen a 13% increase over the past year. With market earnings projected to grow 14% annually, the strong performance of CRISPR's stock could be viewed alongside these generally positive trends and any recent but unspecified developments as contributing factors to its upward momentum in the market. Be aware that CRISPR Therapeutics is showing 1 weakness in our investment analysis. Trump's oil boom is here — pipelines are primed to profit. Discover the 22 US stocks riding the wave. Over the past year, CRISPR Therapeutics' shares experienced a total return of 27.67% decline. This longer-term performance contrasts with the U.S. market's return of 12.6% and the U.S. Biotechs industry return of 9% over the same period. Despite the recent 15.8% increase in CRISPR's stock price over the past month, the longer-term underperformance highlights ongoing challenges. The company's significant net losses and decreasing revenue signal potential hurdles to achieving forecasted revenue growth of 57.32% per year. Earnings forecasts remain bleak, as CRISPR is currently unprofitable and not expected to turn profitable within the next three years. This indicates that while the recent uptick in share price might be aligned with short-term market trends, the company's underlying financial health presents uncertainties. Analyst consensus estimates a fair value price target of US$81.67, which is over twice the current share price. This suggests that the stock is trading at a substantial discount, potentially implying room for future price appreciation if the company can improve its financial metrics. However, it also underscores the risks, given the current unprofitable status and forecasted challenges ahead. Examine CRISPR Therapeutics' past performance report to understand how it has performed in prior years. This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned. Companies discussed in this article include NasdaqGM:CRSP. This article was originally published by Simply Wall St. Have feedback on this article? Concerned about the content? with us directly. Alternatively, email editorial-team@ Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
4 hours ago
- Yahoo
CRISPR Therapeutics (NasdaqGM:CRSP) Sees 16% Stock Price Surge Over Last Month
CRISPR Therapeutics experienced a 15.8% increase in its share price over the past month. While specific recent news on the company was not available to credit for this movement, it's worth noting that during this period, the broader market rose by 1.8%, and has seen a 13% increase over the past year. With market earnings projected to grow 14% annually, the strong performance of CRISPR's stock could be viewed alongside these generally positive trends and any recent but unspecified developments as contributing factors to its upward momentum in the market. Be aware that CRISPR Therapeutics is showing 1 weakness in our investment analysis. Trump's oil boom is here — pipelines are primed to profit. Discover the 22 US stocks riding the wave. Over the past year, CRISPR Therapeutics' shares experienced a total return of 27.67% decline. This longer-term performance contrasts with the U.S. market's return of 12.6% and the U.S. Biotechs industry return of 9% over the same period. Despite the recent 15.8% increase in CRISPR's stock price over the past month, the longer-term underperformance highlights ongoing challenges. The company's significant net losses and decreasing revenue signal potential hurdles to achieving forecasted revenue growth of 57.32% per year. Earnings forecasts remain bleak, as CRISPR is currently unprofitable and not expected to turn profitable within the next three years. This indicates that while the recent uptick in share price might be aligned with short-term market trends, the company's underlying financial health presents uncertainties. Analyst consensus estimates a fair value price target of US$81.67, which is over twice the current share price. This suggests that the stock is trading at a substantial discount, potentially implying room for future price appreciation if the company can improve its financial metrics. However, it also underscores the risks, given the current unprofitable status and forecasted challenges ahead. Examine CRISPR Therapeutics' past performance report to understand how it has performed in prior years. This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned. Companies discussed in this article include NasdaqGM:CRSP. This article was originally published by Simply Wall St. Have feedback on this article? Concerned about the content? with us directly. Alternatively, email editorial-team@ Sign in to access your portfolio
Yahoo
a day ago
- Yahoo
FDA meeting gives window into gene therapy field's angst
This story was originally published on BioPharma Dive. To receive daily news and insights, subscribe to our free daily BioPharma Dive newsletter. Anyone looking for evidence of genetic medicine's enormous promise need only read of KJ Muldoon. The 10-month-old infant headed home from a Philadelphia hospital this week, dressed in a celebratory cap and gown, after his life-threatening disease was successfully treated with a bespoke CRISPR therapy. While baby KJ is not cured, the treatment has stabilized his disease, a rare liver condition known as CSP1 deficiency, to such extent he's able to resume eating a normal diet. Doctors, who hurriedly designed and constructed KJ's custom therapy in a matter of months, have backed off supportive medications and hope he'll no longer need a liver transplant. 'Each year, 10 million babies are born with one of about 10,000 known rare genetic diseases, many of which are, in principle, now treatable with genetic medicines,' David Liu, a pioneering CRISPR scientist whose laboratory helped in KJ's treatment, said at a meeting hosted by the Food and Drug Administration Thursday. 'The opportunity created by this perfect storm moment in scientific, medical, regulatory and manufacturing innovation is to provide on-demand genetic treatments like KJ's at scale.' Yet Liu and 22 other gene therapy experts and advocates who attended Thursday's roundtable didn't travel to the regulator's headquarters in White Oak, Maryland to extol the field's advances. By and large, they came to warn of a crisis. There are now dozens of approved cell and gene therapies in the U.S., some of which offer near-curative potential for serious diseases like spinal muscular atrophy, sickle cell disease and acute lymphoblastic leukemia. However, the sector that's produced these therapies is struggling. Investors have soured on genetic medicine as developers struggle to prove they can profitably sell the complex and often hugely expensive treatments. Biotechnology companies are cutting research, laying off staff and, in some cases, shutting down. Large pharmaceutical firms are no longer willing to bet billions of dollars they can surmount the regulatory and reimbursement hurdles that stand in the way of many of these therapies. And academic labs, still bursting with promising new ideas for technologies like CRISPR, now fear their projects will wither on the vine. 'We estimate that over 100 rare disease gene therapy products that had reached clinical stage have been discontinued since 2023 — not because of treatment failure, but because of the risk of market failure,' said Terence Flotte, dean of the University of Massachusetts' T.H. Chan School of Medicine and president of the American Society of Cell and Gene Therapy. 'The scientific advances that we have witnessed are just nothing short of spectacular. It's not hyperbole,' said Crystal Mackall, a professor at Stanford University and founding director of the cancer cell therapy center there. 'Despite this unconditional scientific success, the field is really struggling to deliver these therapies to all patients who can benefit.' Their warnings found a receptive audience in FDA leadership. Commissioner Martin Makary and top official Vinay Prasad, who leads the office that oversees cell and gene therapies, were sympathetic to experts' arguments and pledged to help. 'We are going to continue the successes of the FDA in facilitating the regulatory process for these conditions and these products,' said Makary. 'We're also going to try to improve by creating more efficiencies.' Prasad, who in the past has criticized the FDA's accelerated approval of a gene therapy for Duchenne muscular dystrophy, showed support for flexible trial designs and endpoints when appropriate for the disease or treatment. He also noted the agency accepts that cell and gene therapies don't always comes with transformative potential. 'We understand that progress is not always made in a single leap,' he added. 'We will consider incremental steps forward, because those add up.' The assembled experts came with lists of possible solutions. Carl June, a famed immunologist and cell therapy researcher at the University of Pennsylvania, called for the U.S. to borrow from the two-tier regulatory system used in China, which allows for medical institutions to more rapidly start first-in-human trials under the supervision of local review boards. Don Kohn, a University of California, Los Angeles scientist who has developed gene therapies, asked the FDA to reduce the requirements for 'comparability' testing when companies transition production from academic to commercial settings. Others emphasized the importance of regulatory awards, like the priority review vouchers granted by the FDA to developers of certain therapies, who often sell them for needed capital. And many called for the agency to share more feedback and lessons learned from the applications they receive from industry. Behind all of their suggestions was a consistent concern: If regulators don't help solve the field's problems, the U.S. risks losing its leadership in developing the kinds of treatments that can cure diseases. 'If we don't adapt, the next generation of treatments will emerge abroad,' said June. 'The future of medicine with cell and gene therapy is at stake.' Their message seemed to be heard by Makary and Prasad, who noted that many of the issues raised are on their radar at FDA. Prasad, for instance, noted that they hope to redact and make available more internal documents to aid developers' understanding of what the FDA is looking for. 'This is not a horse and pony show to say we did this,' added Makary. 'This is an honest listening session.' Recommended Reading A bespoke CRISPR therapy suggests a blueprint for treating 'N-of-1' diseases
